Thomson Healthcare Online Treatment Tools Mark Milestone

Thomson HealthcareMore than one million people have used Thomson Healthcare (NYSE: TOC; TSX: TOC) Profiler treatment option tools to help make treatment decisions for cancer, heart disease and lung disease. "When you consider more than 20 million people are diagnosed with cancer, heart disease or lung disease each year, this is not the kind of milestone one celebrates," said Alicia Moffat, Thomson Healthcare's vice president of Web operations. "It is a significant indicator of the persistence of these conditions in our country and a positive sign that patients and caregivers are taking a proactive approach to disease education, management and treatment."

The tools are unique in their approach to helping people understand their conditions, their possible treatments and the side effects of those treatments. The online Profiler tools are free of charge and accessible under the "treatment decision" links on the American Cancer Society, American Heart Association, and American Lung Association Web sites.

The Thomson Healthcare Profiler tools walk users through a step-by-step approach to a better understanding of their diagnostic tests, treatment options and, in some cases, possible outcomes based on similar people treated within clinical trials. All of the information presented is based on clinical evidence published in leading medical journals. No other Internet offering produces such in-depth treatment information tailored to an individual's clinical status.

Donald Distasio, chief executive officer, Eastern Division of the American Cancer Society and a prostate cancer survivor, says that - even though he was aware of the tools and other information available at the American Cancer Society's cancer.org Web site - he didn't really appreciate the value of knowing his options until he was faced with making those tough treatment decisions for himself.

"There is just an extraordinary depth of information there. Prostate cancer has rather difficult treatment choices to make, and the tool and all the information on the cancer.org site was very reassuring and helpful," Distasio said. "With these tools and information on cancer.org, I felt very comfortable. All my questions had been answered and that makes a world of difference in how you feel going into treatment."

About Thomson Healthcare
Thomson Healthcare is the leading provider of decision support solutions that help organizations across the healthcare industry improve clinical and business performance. Thomson Healthcare products and services help clinicians, hospitals, employers, health plans, government agencies, and pharmaceutical companies manage the cost and improve the quality of healthcare.

Thomson Healthcare is a part of The Thomson Corporation, a provider of value-added information, software tools and applications to professionals in the fields of healthcare, law, tax, accounting, scientific research, and financial services. The Corporation's common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC). For more information, visit www.thomsonhealthcare.com.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...